Domoic Acid as a Lead for the Discovery of the First Selective Ligand for Kainate Receptor Subtype 5 (GluK5).

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Journal of Medicinal Chemistry Pub Date : 2024-08-22 Epub Date: 2024-08-12 DOI:10.1021/acs.jmedchem.4c01311
Silke Buschbom-Helmke, Pengfei Wang, Anna Alcaide, Federico Miguez-Cabello, Mario Carta, Julio S Viotti, Birgitte Nielsen, Christophe Mulle, Derek Bowie, Flemming Steen Jørgensen, Darryl S Pickering, Lennart Bunch
{"title":"Domoic Acid as a Lead for the Discovery of the First Selective Ligand for Kainate Receptor Subtype 5 (GluK5).","authors":"Silke Buschbom-Helmke, Pengfei Wang, Anna Alcaide, Federico Miguez-Cabello, Mario Carta, Julio S Viotti, Birgitte Nielsen, Christophe Mulle, Derek Bowie, Flemming Steen Jørgensen, Darryl S Pickering, Lennart Bunch","doi":"10.1021/acs.jmedchem.4c01311","DOIUrl":null,"url":null,"abstract":"<p><p>Twenty-one simplified analogues of the natural product domoic acid were designed, synthesized, and then characterized at homomeric kainic acid (KA) receptors (GluK1-3,5). <b>LBG20304</b> displays a high affinity for homomeric GluK5 receptors (IC<sub>50</sub> = 432 nM) with a >40-fold selectivity over homomeric GluK1-3 subtypes and ≫100-fold selectivity over native AMPA and <i>N</i>-methyl d-aspartate receptors. Functional studies of <b>LBG20304</b> on heteromeric GluK2/5 receptors show no agonist or antagonist functional response at 10 μM, while a concentration of 100 μM at neuronal slices (rat) shows low agonist activity. A molecular dynamics simulation of <b>LBG20304</b>, in a homology model of GluK5, suggests specific interactions with the GluK5 receptor and an occluded ligand binding domain, which is translated to agonist or partial agonist activity. <b>LBG20304</b> is a new compound for the study of the role and function of the KA receptors with the aim of understanding the involvement of these receptors in health and disease.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":" ","pages":"14524-14542"},"PeriodicalIF":6.8000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c01311","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Twenty-one simplified analogues of the natural product domoic acid were designed, synthesized, and then characterized at homomeric kainic acid (KA) receptors (GluK1-3,5). LBG20304 displays a high affinity for homomeric GluK5 receptors (IC50 = 432 nM) with a >40-fold selectivity over homomeric GluK1-3 subtypes and ≫100-fold selectivity over native AMPA and N-methyl d-aspartate receptors. Functional studies of LBG20304 on heteromeric GluK2/5 receptors show no agonist or antagonist functional response at 10 μM, while a concentration of 100 μM at neuronal slices (rat) shows low agonist activity. A molecular dynamics simulation of LBG20304, in a homology model of GluK5, suggests specific interactions with the GluK5 receptor and an occluded ligand binding domain, which is translated to agonist or partial agonist activity. LBG20304 is a new compound for the study of the role and function of the KA receptors with the aim of understanding the involvement of these receptors in health and disease.

Abstract Image

以多莫酸为先导,发现凯纳特受体亚型 5 (GluK5) 的首个选择性配体。
我们设计、合成了天然产物多莫酸的 21 种简化类似物,然后对同源凯尼酸(KA)受体(GluK1-3,5)进行了表征。LBG20304 对同源 GluK5 受体具有高亲和力(IC50 = 432 nM),对同源 GluK1-3 亚型的选择性大于 40 倍,对原生 AMPA 和 N 甲基 d-天冬氨酸受体的选择性大于 100 倍。LBG20304 对异构体 GluK2/5 受体的功能研究表明,在 10 μM 浓度下没有激动剂或拮抗剂功能反应,而在神经元切片(大鼠)上的 100 μM 浓度则显示出较低的激动剂活性。在 GluK5 的同源模型中对 LBG20304 进行的分子动力学模拟表明,它与 GluK5 受体和闭锁的配体结合域之间存在特异性相互作用,从而产生了激动剂或部分激动剂活性。LBG20304 是研究 KA 受体作用和功能的一种新化合物,目的是了解这些受体在健康和疾病中的参与情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信